The Longevity Reality Radar
46 approaches, rated by evidence.

GLP-1 drugs for brain health

GLP-1 analogs (repurposed) for brain health. Brain & neurodegeneration. Reviewed Jul 2026.

Early signals of better memory, but large trials are still running and no brain benefit is proven.

Stage
Phase 2/3
Rung: In human trials. Phase 1 to 3. Being tested in people now. Most will not make it.
Evidence grade
C
emerging data
Small or uncontrolled human data, or strong animal data. How grades work.

What it is

The same drug class behind Ozempic/Wegovy, now being tested to protect neurons and slow dementia.

The evidence

Emerging data suggests improved memory and slower neurodegeneration; large trials ongoing within a 192-trial / 158-agent 2026 Alzheimer's pipeline.

What you can do today

Outside a registered clinical trial, this is not something you can responsibly get. If it is relevant to you, the route is a trial: ask your specialist, or search a trial registry such as ClinicalTrials.gov for studies you may qualify for.

Sources

  • Official or company statementalz.org

No primary paper or registry record is linked for this entry yet. The evidence summary names the studies it relies on.

Change history

No ladder moves or corrections logged for this entry yet. Changes are dated on the change log.

Related

More in Brain & neurodegeneration

All 5 in Brain & neurodegeneration.

  • Lecanemab and donanemabGrade A, outcome RCTs. Approved.Slows cognitive decline by about 27 to 35% in early Alzheimer's, which is not a cure, and brain swelling or bleeding is a real risk.
  • 40 Hz light and sound for Alzheimer'sGrade C, small human trial. Phase 3, no results yet.Strong mouse data and one small human feasibility trial, but the Phase 3 has not reported and human efficacy is not established.
  • Stem-cell therapy for Parkinson'sGrade C, small cohorts. Phase 1/2, conditional approval in Japan.Motor symptoms eased or stabilised for up to two years in small cohorts, with no large randomised results yet.
  • Psilocybin for brain agingGrade D, one case report. Speculative.A single Alzheimer's case report and preliminary lab data, not a basis for treating brain aging.